Adherence to antiviral therapy is a significant issue for HIV-infected drug abusers. The combined studies of lenfivirus-infected rodent and rhesus macaques proposed here build upon exciting preliminary data obtained on nanoformulafions of anfiretrovirals (nanoART) and the data that will result from projects 1 and 2 (A. Kabanov and H. Gendelman). Before proceeding to nonhuman primate studies, rodent testing of nanoART in virus-infected EcoHIV and/or humanized mice. These studies will be conducted with D. Volsky and L. Poluektova. Thus, we will begin in Aim 1 performing rodent biodistribufion (including bioimaging) and pharmacokinefic (PK) tesfing (years 1 and 2, using cores B and C, M. Boska and C. Fletcher) in infected animals as a first pass screen for antiretroviral efficacy and tissue toxicities in vivo (oversight and biostafisfician support through core A, H. Gendelman). We will then proceed in specific aim 2 for PK, drug tissue distribufion, and safety studies in uninfected nonhuman primates (year 3), and then in specific aim 3 perform nanoART evaluafions in SHIV-infected monkeys, including PK, imaging, and efficacy studies, with extensive tissue analyses (years 3-5). These studies will predict whether long-spaced dosing protocols would yield acceptable drug plasma levels in monkeys and whether such developed protocols are efficacious against virus in primates. In toto, studies in the SHIV/rhesus monkey model will yield important information immediately applicable to future human clinical trials. The wealth of data, from pharmacokinefics, organ distribufion, effects on the virus, immune and other physiological systems are crucial pre-clinical steps in the development ofthis excifing therapeufic development.
In the United States and in resource-limited setfings, HIV-1 infecfion remains a serious problem, contributing to morbidity and mortality of people often in the prime of life. One major difficulty and impediment to maintaining health is the frequent and regular dosing of medicafions;this is especially problemafic in those who are substance abusers. The strategies to be tested here are designed to address this impediment leading to improved health of these individuals as well as lowering potenfial transmission of HIV to others
| Forsberg, Erica M; Huan, Tao; Rinehart, Duane et al. (2018) Data processing, multi-omic pathway mapping, and metabolite activity analysis using XCMS Online. Nat Protoc 13:633-651 |
| Thomas, Midhun B; Gnanadhas, Divya Prakash; Dash, Prasanta K et al. (2018) Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine (Lond) 13:2139-2154 |
| Kiyota, Tomomi; Machhi, Jatin; Lu, Yaman et al. (2018) URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease. J Neuroinflammation 15:137 |
| Guijas, Carlos; Montenegro-Burke, J Rafael; Warth, Benedikt et al. (2018) Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol 36:316-320 |
| Beyer, Brittney A; Fang, Mingliang; Sadrian, Benjamin et al. (2018) Metabolomics-based discovery of a metabolite that enhances oligodendrocyte maturation. Nat Chem Biol 14:22-28 |
| Herskovitz, Jonathan; Gendelman, Howard E (2018) HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication. J Neuroimmune Pharmacol : |
| Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276 |
| McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62: |
| Ottemann, Brendan M; Helmink, Austin J; Zhang, Wenting et al. (2018) Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials 185:174-193 |
| Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65 |
Showing the most recent 10 out of 141 publications
